The Diagnostic CDMO Market segmentation framework, as detailed in this Diagnostic CDMO Market Report, provides a comprehensive and strategically rich view of the industry across four key dimensions: service, device class, application, and end use. This multi-dimensional segmentation enables stakeholders to identify the most commercially significant service and application categories, understand the regulatory and clinical drivers behind segment leadership, and align investment, partnership, and market entry strategies with the highest-value growth opportunities in the diagnostic outsourcing ecosystem. The market is valued at US$ 44.12 billion in 2025 and is forecast to reach US$ 105.24 billion by 2033 at a CAGR of 11.48%.

Request Sample Pages of this Research Study @ https://www.businessmarketinsights.com/sample/BMIPUB00032349

By Service

The service segment encompasses contract manufacturing, contract development, packaging, labeling and sterilization, regulatory affairs, and others. Contract manufacturing serves as the market's financial anchor, accounting for nearly half of all revenue, as global OEMs migrate away from in-house production to optimize supply chains and reduce capital expenditure across accessories, assembly, component, and device manufacturing sub-categories. Contract development is the fastest-growing service segment, driven by the precision medicine boom requiring sophisticated end-to-end design, testing, validation, and quality management services for high-complexity diagnostic device development programs. Regulatory affairs services are experiencing elevated demand in Europe driven by the EU IVDR implementation, which has significantly increased the regulatory compliance burden for diagnostic device manufacturers and created strong demand for CDMOs with high-tier regulatory expertise.

By Class

The class segment covers Class I, Class II, and Class III medical devices. Class II devices dominate the market through the high volume of infectious disease diagnostic kit manufacturing that constitutes the largest global diagnostic manufacturing category. Class III devices represent the highest-growth and highest-value class segment, driven by the precision medicine and companion diagnostics boom requiring sophisticated high-risk diagnostic tools with the most rigorous regulatory pathway requirements. The technical barrier for Class III device manufacturing is high, creating competitive moats for CDMOs with validated Class III manufacturing capabilities.

By Application

The application segment covers infectious disease diagnostics, oncology diagnostics, cardiometabolic diagnostics, genetic and genomic testing, respiratory and critical care diagnostics, and others. Infectious disease diagnostics leads through the highest global test volume driven by POC and rapid test demand. Oncology diagnostics and genetic and genomic testing represent the highest-value growth applications, fueled by companion diagnostic co-development and precision oncology biomarker testing program expansion.

By End Use

OEMs represent the largest end-use segment as the primary customers of CDMO contract manufacturing and development services. Pharmaceutical and biopharmaceutical companies are the fastest-growing end-use segment, driven by the expanding companion diagnostic co-development market.

About Us

Business Market Insights is a one-stop industry research provider of actionable intelligence. Specializing in industries including Manufacturing and Construction, Semiconductor and Electronics, Healthcare, and more, the firm publishes over 500 research reports annually.

Contact Us

If you have any queries about this report or if you would like further information, please contact us: Phone: +16467917070 E-mail: [email protected]